PDC Biotech plans trial of peptide to treat primary dysmenorrhoea
This article was originally published in Scrip
Executive Summary
PDC Biotech, a privately held Austrian biopharmaceutical development company, is about to start a Phase I trial of PDC31 to treat otherwise healthy women with primary dysmenorrhoea, a disabling condition found in 10-15% of women of childbearing age which causes severe abdominal pain. The Phase I trial will be conducted at three clinical sites in Austria and in Germany and will evaluate the safety and pharmacokinetics of the compound as well as its effects on uterine contractility.